AirSculpt Cuts 2026 Outlook After Same-Center Case Drop

The Tip Desk · November 6, 2026 · 3 min read

Third-quarter revenue was $31.9 million and Adjusted EBITDA was $0.4 million as the company lowered full-year revenue guidance to about $144 million to $146 million.

AirSculpt Technologies (AIRS), a national provider of premium body contouring procedures, cut its full-year 2026 revenue and Adjusted EBITDA outlook after same-center case volume reversed a second-quarter gain.

For the three months ended September 30, 2026, revenue was $31.9 million, down 8.7% from $35.0 million a year earlier. Same-center cases fell 9.6% to 2,483 from 2,748 a year earlier, reversing the 1.0% same-center case increase reported in the second quarter. Revenue per case on a same-center basis rose 2.3% to $12,865 from $12,574.

Chief Executive Officer Yogi Jashnani said third-quarter results were below expectations and that the company identified key drivers it is addressing with a sense of urgency. He said the quarter saw progress on priorities, including expanding GLP-1-related procedures. The company performed approximately 250 such procedures, about 10% of total cases.

Adjusted EBITDA was $0.4 million, down from $3.0 million a year earlier, and Adjusted EBITDA margin compressed to 1.2% from 8.7%. Net loss was $7.2 million, an improvement of $2.3 million from a $9.5 million net loss in the fiscal 2025 third quarter. Loss per share was $0.10, compared with $0.15 a year earlier.

The company is reducing full-year 2026 revenue guidance to approximately $144 million to $146 million from the previous range of $151 million to $157 million. Adjusted EBITDA guidance is now approximately $9 million to $10 million, compared with the prior range of $12 million to $14 million. Jashnani said the company reduced guidance to reflect third-quarter performance continuing through year-end and remains confident in its strategy.

In the first nine months of 2026, revenue was $114.2 million, down 3.5% from $118.4 million in the first nine months of fiscal 2025. Case volume was 8,941, a 2.1% decrease on a same-store sales basis. Net loss was $10.7 million, an improvement of $2.3 million from a $13.0 million net loss a year earlier. Adjusted EBITDA was $8.6 million, down $4 million from $12.6 million.

As of September 30, 2026, cash and cash equivalents were $15.2 million, with $5.0 million of borrowing capacity under the revolving credit facility and gross debt of approximately $37.2 million. During the third quarter the company raised $7.2 million from an at-the-market offering and paid down $7.0 million of debt.

On November 5, 2026, after quarter-end, AirSculpt entered a Blue Torch financing agreement with a syndicate of lenders, including a $39.0 million senior secured term loan funded in full and a $5.0 million revolving commitment, none of which was drawn at closing. The term loan matures November 5, 2031. Proceeds were used to repay in full and terminate the existing credit agreement and to pay related fees.

The company operated 31 facilities and 65 procedure rooms at September 30, 2026.